and/or node-negative HER2 þ tumors, were less likely to receive anti-HER2 therapy. Barriers to accessing trastuzumab are multifactorial and include issues related to drug funding and high treatment costs for patients that have been reported worldwide. Herein, we review available literature on the use of, and barriers to, treatment with trastuzumab in patients with HER2 þ breast cancer. We also discuss how the availability of safe and effective biosimilars might increase access to trastuzumab and allow greater use of anti-HER2 therapy, potentially improving patient outcomes.
Introduction
Between 15% and 20% of patients with breast cancer have HER2-positive (HER2 þ ) disease. 1, 2 Trastuzumab, a recombinant humanized monoclonal antibody against HER2, was approved by the US Food and Drug Administration (FDA) in 1998 and the European Medicines Agency (EMA) in 2000 for use in patients with HER2 þ metastatic breast cancer (MBC). 3, 4 Subsequently, trastuzumab was approved by the EMA and FDA as adjuvant therapy (2006) and by the EMA as neoadjuvant therapy (2011) for patients with HER2 þ early breast cancer (EBC). 3, 4 Furthermore, in 2015, trastuzumab was added to the World Health Organization (WHO) Model List of Essential Medicines. 5 Targeted therapy with trastuzumab and/or other currently available HER2-directed agents, including pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1), is standard treatment for patients with HER2
þ breast cancer, and clinical guidelines recommend trastuzumab-based chemotherapy (along with pertuzumab) as (neo)adjuvant treatment for HER2 þ EBC and in the metastatic setting. [6] [7] [8] [9] [10] Although trastuzumab was initially evaluated and used in the first-line metastatic setting, 11 in some countries it became common practice to continue trastuzumab at progression, which improves patient outcomes. 12 However, multiple lines of HER2 blockade, as well as combinatorial treatment strategies, have significant cost implications for patients and health care systems. Patents for several biologic drugs, including trastuzumab, have recently expired or will soon expire, 13 which has stimulated the development of biosimilars. Biosimilars are biologic products that are highly similar to a licensed biologic (ie, the reference or originator product), "notwithstanding minor differences in clinically inactive components," and have no clinically meaningful differences in safety, purity, or potency compared with the reference product. [14] [15] [16] Bio-
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Patterns of Use in EBC
In a 2011 international physician survey, 92% of respondents (N ¼ 151) indicated that they routinely recommend 1 year of adjuvant trastuzumab; however, 47% reported having at least 1 case within the previous year in which trastuzumab was recommended but treatment could not be started. 19 Failure to start recommended trastuzumab was more commonly reported by physicians from lowand middle-income countries (75%) than high-income countries (40%; P ¼ .005) and most often cited by respondents from Africa (100%), Asia (89%), and Latin America (80%). 19 Observational studies on real-world treatment patterns in patients diagnosed with and/or treated for HER2 þ EBC between 2005 and 2015 suggest that 19.1% to 59.5% in the United States, Canada, Australia, New Zealand, United Kingdom, The Netherlands, Germany, and China did not receive neoadjuvant or adjuvant trastuzumab (Table 1) . [23] [24] [25] [30] [31] [32] [34] [35] [36] [37] [39] [40] [41] 44, 45 Use of trastuzumab was somewhat less in patients with small ( 1 cm) and/or node-negative HER2 þ tumors, 28, 30, 40, 41, 44 in whom the benefits of adjuvant trastuzumab therapy are somewhat controversial. 7, 9, 10 Several studies conducted between 2006 and 2013 also suggest that older patients with HER2
þ EBC and patients with HER2 þ /hormone receptor (HR)-positive disease were less likely to receive trastuzumab-based therapy (Table 1) . 24, 30, 34, 35, 39, 41 Of these patients, approximately 50% of those aged 65 years or older in the United States, 47.1% (32 patients) older than 69 years in Germany, and 67% (176 patients) older than 70 years in Australia and New Zealand did not receive trastuzumab-based therapy (Table 1) . 34, 35, 39, 41 Lesser use of trastuzumab in older patients might reflect, in part, increased comorbidities. However, among women of this older age group in the United States, those who resided in impoverished neighborhoods or who were black were less likely to receive trastuzumab-based therapy (Table 1) . 35, 39 Similar to the overall population, older women with more favorable disease characteristics, including those with HR þ tumors, small tumors, or no lymph node involvement, were also less likely to receive adjuvant trastuzumab.
35,39
Patterns of Use in MBC
A prospective, US-based observational cohort study (registHER) that enrolled patients with HER2
þ MBC between 2003 and 2006 reported that approximately 12% (121 patients) did not receive first-line trastuzumab-based systemic therapy (Table 2) . 22, 26, 27, 29, 33, 38, 42, 43, 45 
Reasons for Patients Not Receiving Anti-HER2 Therapy
Few studies in patients with EBC, and none in patients with MBC, reported reasons for patients not receiving anti-HER2 therapy. 23, 25, 30, 32, 36, 37, 40, 44 Furthermore, it is not clear how often HER2 blockade is continued in multiple lines of systemic therapy for metastatic disease. In the adjuvant setting (Table 1) , trastuzumab was withheld from patients because of advanced age (11%-23%), increased risk of cardiac toxicity (15%-46.4%), or other comorbidities (approximately 12%). 23, 25, 36, 37, 40 In other cases,
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Need for Trastuzumab Biosimilar for HER2-Positive Breast Cancer patients declined systemic therapy or specifically refused trastuzumab (11.9%-25%) or their oncologist advised against its use because of a perceived low risk of recurrence or unfavorable riskebenefit ratio (10.7%-30.5%). 23, 25, 32, 36, 37, 40, 44 Less frequently (2%-15.3%), trastuzumab was withheld because of other patient-related factors (eg, loss to follow-up, general frailty/poor performance status) or disease characteristics (Table 1) . 23, 25, 36, 37, 40 In 1 United Kingdom-based study conducted 23, 25, 36, 40 In addition, the prevalence of cardiovascular disease might be associated with demographic factors (eg, age or race), 48 which could explain, at least in part, why certain patient subgroups appeared less likely to receive HER2-targeted therapy. Nevertheless, real-world data show that not all patients with HER2 þ breast cancer receive HER2-targeted agents, suggesting there might be opportunities for increasing access to optimal anti-HER2 therapy.
Barriers to Accessing Trastuzumab
Physicians might decide not to prescribe anti-HER2 therapy in situations where such treatment has regulatory approval but is not funded or reimbursed. A survey of oncologists in the United States and emerging markets (Brazil, Mexico, Turkey, and Russia) showed that most physicians reported "always" or "frequently" prescribing trastuzumab for patients with HER2
þ breast cancer (neoadjuvant, 73%; adjuvant, 92%; metastatic, 92%). However, 31% (between 10% in the United States and 76% in Russia) of physicians in these countries reported there had been at least 1 instance in which they had to cancel or delay treatment because of reimbursement issues, although it was not stated how often this precluded trastuzumab use. 21 Furthermore, among the small percentage of respondents who reported "not so often," "rarely," or "never" prescribing trastuzumab, between 37% and 49% considered lack of drug funding a barrier to use in the neoadjuvant, adjuvant, and metastatic settings. 21 Reimbursement of anti-HER2 therapy also varies across Europe, which might create disparities in accessing trastuzumab. 20 For example, trastuzumab is on formulary and available at low or no out-of-pocket cost to patients with HER2 þ breast cancer throughout Western Europe; however, in several Eastern European countries it is not reimbursed or as highly subsidized as in Western Europe, leaving patients responsible for up to the full cost of treatment. 20 Reimbursement decisions are complex and might be influenced by several factors. 49 In many countries, cost-effectiveness information is considered when making decisions about drug funding and reimbursement. Economic evaluations of trastuzumab-based adjuvant systemic therapy performed in high-income countries show that trastuzumab is a highly cost-effective intervention for most patients. [50] [51] [52] However, trastuzumab-based adjuvant systemic therapy is not considered cost-effective in several Latin American countries 53 and, like many therapeutic options, uncertainties remain regarding its cost-effectiveness in the metastatic setting. 54 This might be of particular relevance to patients who receive multiple lines of HER2 blockade for treatment of metastatic disease, because the most clinically effective sequence might not be considered costeffective and, therefore, might not be reimbursed. 55 Controversies surrounding the cost-effectiveness of trastuzumab might contribute to its limited accessibility in some patients and regions.
Another consideration for reimbursement is off-label regulations. 49 Public and/or private payers might not reimburse off-label indications or might provide coverage of off-label indications only when there is sufficient evidence to support that use. 49 This might be relevant to certain subpopulations of patients with HER2 þ breast cancer. For example, guidelines recommend trastuzumab-based adjuvant chemotherapy as an option for patients with small nodenegative HER2 þ tumors, because this patient population remains at higher risk of recurrence than those with node-negative HER2 À tumors of the same size. 7,9,10 However, direct evidence for efficacy of trastuzumab in small, node-negative HER2 þ breast cancer is lacking, reflecting the design of registration studies, and trastuzumab is not approved for use in this setting. 3, 4, 7, 9, 10 As a result of reimbursement strategies, some patients might face greater economic burden, which might create a barrier to accessing treatment. [19] [20] [21] Among surveyed oncologists in the United States and emerging markets who reported that they "not so often," "rarely," or "never" use trastuzumab, 34% (of 137 respondents) and 42% (of 41 respondents) cited "high out-of-pocket treatment cost for patient" as a barrier to use in the neoadjuvant and adjuvant settings, respectively. 21 In an international survey of physicians (N ¼ 151) conducted in 2011, 27% of respondents who reported at least 1 instance within the previous year in which adjuvant trastuzumab was recommended to a patient who ultimately did not receive it cited cost as the reason for withholding treatment. 19 Furthermore, cost was more often cited by physicians in low-and middle-income countries (73%) than in high-income countries (7%; P < .0001) as a reason for withholding adjuvant trastuzumab. 56 Biologics such as trastuzumab are high molecular-weight proteins, often containing post-translational modifications, with complex 3-dimensional structures that are difficult to fully characterize. 56 Unlike small-molecule drugs, biologics are produced in living systems through a series of biological reactions that are inherently variable and sensitive to manufacturing and environmental conditions. 56 Because this has been long recognized, biologic manufacturing is characterized by heterogeneity of the same biologic product produced by different manufacturers and within/between batches from the same manufacturer.
Manufacturers of an originator biologic have extensive knowledge about the manufacturing process of their product. 57 This information is considered proprietary and confidential; therefore, it is not accessible to biosimilar manufacturers. For this reason, and because of their complexity and heterogeneity, biologics cannot be exactly replicated, so the concept of a generic equivalent and regulatory approval requirements for small-molecule generics cannot be applied to biologics. 14, 16 Therefore, regulatory agencies such as the EMA and FDA, as well as the WHO, have issued guidelines for the approval of biosimilars. [14] [15] [16] All agencies require a rigorous stepwise approach to comparing biosimilar and reference products that begins with extensive structural and functional characterization ( Figure 1 ). [14] [15] [16] 58 Depending on the outcome of analytical (structural) and in vitro functional assessments, nonclinical in vivo testing might be conducted to further evaluate drug safety, [14] [15] [16] if deemed necessary. Animal toxicity studies should show high similarity between the proposed biosimilar and reference products in terms of their pharmacokinetics (PK) and pharmacodynamics (PD). 15, 16 These studies might also include immunogenicity assessments to support the interpretation of nonclinical results. 15, 16, 59 Nonclinical assessments are followed by a limited number of comparative clinical trials that are designed to show a high degree of pharmacologic (PK/PD) and clinical (safety, efficacy, and immunogenicity) similarity to the reference product. [14] [15] [16] 59 In the United States, biosimilars are approved following a pathway established by the Biologics Price Competition and Innovation Act of 2009, which places greater emphasis on findings from analytical and functional assessments than a full reference or originator biologics application. 15, 60 When analytical and functional similarity are established, biosimilar approval might rely, in part, on the safety and efficacy data that supported the approval of its reference product, thereby reducing the extent of clinical testing compared with that required for originator biologics. 16, 60 The need
for clinical testing to demonstrate similarity in drug safety and efficacy between the proposed biosimilar and reference product also distinguishes the biosimilar pathway from that of small-molecule generics.
Factors to Consider When Evaluating Trastuzumab Biosimilars
The key to developing high-quality biosimilars rests on a demonstration of physicochemical and functional similarity. [14] [15] [16] The large size and complex structure of trastuzumab, as well as differences in manufacturing processes, create the potential for heterogeneous biologic products. Therefore, comparative physicochemical analyses should be selected to detect differences in primary (ie, amino acid sequence), secondary, and higher-order structures, post-translational modifications, product isoforms, and product-related impurities (eg, protein aggregates; Figure 2 ). [14] [15] [16] 61, 62 To evaluate differences in biologic activity, in vitro studies that measure target binding, tumor cell growth inhibition, and antibody-dependent, cell-mediated cytotoxicity should be selected. 16, 63 On the basis of the totality of the evidence from the preceding steps, a comparative clinical pharmacology (PK/PD) study and a comparative clinical efficacy trial (or trials), including clinical immunogenicity and safety assessments, are conducted to investigate whether there are clinically meaningful differences between a proposed biosimilar and reference product. [14] [15] [16] 59 This is in contrast to new drug approvals, which require that large phase III clinical trials are conducted in each indication for which licensure is sought. In some cases, efficacy end points that are selected for biosimilar clinical trials will differ from those used in pivotal trials that led to approval of the originator. Furthermore, whereas phase III trials to support new drug approvals are designed to establish "significant" benefit over a comparative agent, which is usually the current standard treatment, biosimilarity studies are designed to show that differences between treatment groups are not clinically meaningful (ie, are small enough that the biosimilar is considered neither superior nor inferior to the reference product and vice versa). 16, 64 To this end, the most suitable design for biosimilarity studies is a statistically driven equivalence trial in which equivalence is shown when a given parameter (eg, the confidence interval [CI]) falls within the lower and upper limits of a predetermined equivalence margin. 64 Regulatory guidelines for biosimilar development recommend using patient populations, treatment settings, and clinical end points that are adequately sensitive to detect all clinically meaningful differences in efficacy, safety, and immunogenicity between a biosimilar and reference product. 15 Regulatory agencies might also approve a biosimilar for use in other indications for which it has not been studied in a comparative clinical trial with the reference product but for which the reference product is approved; this is known as "extrapolation." 14, 16, 65 For example, extrapolation of data from comparative clinical studies that establish biosimilarity in HER2 þ EBC (eg, neoadjuvant setting) or in patients with metastatic disease could support the approval of trastuzumab biosimilars for use in other indications of trastuzumab. However, extrapolation of data must be scientifically justified on the basis of the totality of the data from all stages of biosimilar development and other evidence that shows the reference product has
Need for Trastuzumab Biosimilar for HER2-Positive Breast Cancer similar therapeutic effects in the studied and extrapolated indications. This concept of extrapolation is consistent with the objective of biosimilar development, because it reduces or eliminates the need for duplicative clinical studies. However, it is in contrast to the development of originator drugs, for which specific clinical trial data are required for each indication for which licensure of the product is sought. It is unclear how receptive clinicians will be to the concept of extrapolation. Although the EMA and FDA guidelines for regulatory approval of biosimilars continue to evolve, products that have been approved using this pathway have undergone rigorous comparative assessments to show similarity to a licensed biologic at all stages of the development process, including in a clinical study or studies. In contrast, oncologists should be aware of "noncomparable biotherapeutic products," also known as "intended copies," that have been introduced as biosimilars in some countries (eg, Russia, China, and India) where stringent regulatory pathways for biosimilar approval had not yet been established or were under development at the time these agents were approved. [66] [67] [68] Intended copies are not truly biosimilars in the context of this review or widely accepted regulatory perspectives, because they have not met EMA, FDA, or WHO requirements for establishing biosimilarity. 67 In other words, regulatory approval for intended copies did not follow a comparative development pathway with the reference biologic and/or the scientific and clinical evidence used to support the approval is incomplete or absent. 67 Therefore, intended copies might represent a risk to patient safety and drug efficacy because the quality and clinical profile of these products have not been as fully characterized as would be a true biosimilar. A "similar biologic" was approved by the Drugs Controller General of India in 2013 as a trastuzumab biosimilar and is marketed under the brand name CanMAb (Biocon Ltd, Bengaluru, India), but this product should be considered an intended copy because it was not evaluated using strict criteria for showing biosimilarity to originator trastuzumab. 69 The WHO has issued recommendations for regulatory risk assessment of biologic products licensed following a generic pathway or with limited analytical, nonclinical, and/or clinical evidence. 70 These guidelines might help address concerns regarding the safety and efficacy of intended copies.
Current Development Status of Biosimilar Trastuzumab
Several trastuzumab biosimilars are in development and comparative clinical PK studies in healthy volunteers have shown pharmacologic equivalence and similar immunogenicity and safety profiles between ABP 980 (Amgen, Thousand Oaks, CA), Hercules/Myl-1401O (Mylan NV, Canonsburg, PA), PF-05280014 (Pfizer Inc, New York, NY), and SB3 (Samsung Bioepis Co, Incheon, South Korea) and their respective trastuzumab reference products. 61, [71] [72] [73] [74] Comparative clinical studies have also shown PK similarity of BCD-022 (Biocad, Saint-Petersburg, Russia) 
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and CT-P6 (Celltrion, Incheon, South Korea), each given in combination with paclitaxel, to originator trastuzumab, also in combination with paclitaxel, in patients with HER2 þ MBC. 75, 76 Clinical trials comparing safety and efficacy of these proposed or approved trastuzumab biosimilars in patients with EBC or MBC are ongoing (Table 3) . Primary end points include measures of tumor response, such as pCR in the neoadjuvant setting and ORR in the metastatic setting. Secondary end points vary, but include additional measures of efficacy, such as event-free, progression-free, and overall survival, as well as measures of safety and immunogenicity (ie, antidrug and neutralizing antibodies). To date, results from some of these trials have only been disclosed at international oncology congresses. 78, 82, 84, 94, 95, 98, 99 A study in patients with HER2 þ EBC comparing neoadjuvant treatment with the proposed trastuzumab biosimilar ABP 980 and originator trastuzumab, each after run-in anthracycline-based chemotherapy, The 2-sided 90% CIs for RD and RR of pCR were contained within the equivalence margins (AE13.0% and 0.759-1.318, respectively). c The 95% CI for the treatment difference was within the equivalence margin (AE0.15). The lower limit of the 95% CI for the stratified difference between groups was above the noninferiority margin (À12.5%).
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i Includes IRR, left ventricular systolic dysfunction, and congestive heart failure. j The 90% CI for the ratio of bpCR was within the prespecified equivalence margin (0.785-1.546); the lower margin of the 95% CI for the difference between bpCR rates was contained within and the upper margin was outside of the predefined equivalence margin (AE13%).
showed clinical equivalence between the 2 products on the basis of central independent review of pCR (47.8% and 41.8%, respectively), and comparable safety profiles, with 292 (80.2%) and 287 (79.5%) patients, respectively, reporting 1 or more adverse events. 78 The efficacy and safety of neoadjuvant CT-P6 and originator trastuzumab, each in combination with chemotherapy, were compared in patients with HER2
þ EBC. 84 The The trastuzumab biosimilar SB3 and originator trastuzumab, each given with chemotherapy, were compared as neoadjuvant treatment for HER2 þ EBC. 98, 99 Results showed equivalence in efficacy between treatments on the basis of the ratio of breast pCR (1.259; 51.7% for SB3 vs. 42.0% for originator trastuzumab), for which the 90% CI (1.112-1.426) was within the predefined equivalence margin (0.785-1.546). 98 Furthermore, 1-year safety, immunogenicity, and survival profiles were also similar between SB3 and originator trastuzumab. 99 Published data from a study in patients with HER2 þ MBC showed comparability between CT-P6 and trastuzumab, each treatment in combination with paclitaxel, with respect to ORR and the incidence of adverse events. 86 Results from a trial comparing the efficacy of Hercules/Myl-1401O versus trastuzumab, each in combination with paclitaxel or docetaxel, as first-line treatment in patients with HER2 þ MBC showed equivalence in efficacy and comparable safety (Table 3) . 89 Reported 24-week ORR was 69.6%
(160 patients) in the Hercules/Myl-1401O group and 64.0% (146 patients) in the trastuzumab group, and the incidence of patients with at least 1 treatment-emergent adverse event was 96.8% (239 patients) in the Hercules/Myl-1401O group and 94.7% (233 patients) in the trastuzumab group. 89 An application for marketing authorization for ABP 980 was submitted to the EMA and to the FDA. 79, 80 A marketing authorization application for CT-P6 was approved by the EMA, and submitted to the Ministry of Health, Labor and Welfare in Japan, and to the FDA. 80, 87, 88 A resubmitted application for marketing authorization for Hercules/Myl-1401O was accepted for review by the EMA; an application for marketing authorization for Hercules/ Myl-1401O was approved by the FDA. 90, 91 A marketing authorization application for PF-05280014 was submitted to the EMA and to the FDA. 96 Finally, a marketing authorization application for SB3 was approved by the EMA, and an application for marketing authorization for SB3 was submitted to the FDA. 100 
Economic Effect of Biosimilars
The regulatory framework for biosimilars provides a more tailored pathway for approval compared with originator biologics that relies on a rigorous assessment of similarity. As a result, biosimilars might provide a lower-cost alternative to originator biologics and have the potential to generate cost savings. Anticipated pricing for biosimilars is approximately 20% to 30% lower than originator biologics. 101 Recent studies of biosimilar pricing in Europe reported discounts generally ranging from 5% to 35% over originator biologics, although discounts of up to 75% were noted in some cases. [102] [103] [104] [105] In general, price discounts for biosimilars might be considered modest compared with small-molecule generics, which can be priced 80% to 90% lower than the brand-name counterpart. [101] [102] [103] [104] [105] This difference is explained in part by the greater complexity of biosimilars in terms of their structure and manufacturing process compared with chemically synthesized, small-molecule generics, which leads to higher development costs ($100-$200 million vs. $1-$5 million) and longer development timelines (8-10 years vs. 3-5 years).
101
A 2016 report estimated the introduction of biosimilars to generate cumulative potential savings of V49 billion (20% discount) to V98 billion (40% discount) in France, Germany, Italy, Spain, the United Kingdom, and the United States between 2016 and 2020. 106 Pharmacoeconomic evaluations have been conducted for different biosimilars to estimate their potential savings and effect in different countries. To date, only 1 budget impact analysis has been conducted for biosimilar trastuzumab. 107 In this analysis introduction of trastuzumab biosimilars in Croatia was estimated to generate potential savings varying from V0.26 million (15% price discount) to V0.69 million (35% price discount) that could be reinvested to treat an additional 14 (15% price discount) to 47 (35% price discount) patients. 107 The extent of cost savings achieved with biosimilars will depend on many factors; thus, drug price in and of itself is not sufficient to understand the potential savings. 106, 108, 109 An important consideration will be future trends in biologic drug utilization. 109 Trastuzumab was first introduced as an intravenous formulation, 3, 4 but in 2013 a subcutaneous formulation was approved by the EMA for treatment of early or metastatic HER2 þ breast cancer. 110 Subcutaneous trastuzumab has shown noninferiority in PK and efficacy
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and a safety profile that is similar to intravenous trastuzumab. [111] [112] [113] [114] Furthermore, subcutaneous trastuzumab is administered over a shorter period of time than intravenous trastuzumab (5 minutes vs. 30-90 minutes) and might be preferred by patients. 4, 113 Trastuzumab biosimilars might provide a lower-cost alternative to originator trastuzumab. However, in many institutions this price reduction for biosimilars might be outweighed by savings associated with use of subcutaneous administration of originator trastuzumab, especially because budgets for drug purchase, pharmacy, and the chemotherapy suite might be independent and held separately. The potential effect of biosimilars on health care budgets and patient access to biologic therapy is significant, including in countries where cost is already a major issue. For example, 53%, 63%, and 81% of physicians surveyed in the countries of Brazil, Mexico, and Russia reported they would increase the use of HER2 therapy for treatment of HER2 þ breast cancer if a lower cost trastuzumab biosimilar was available. 21 In addition, with current drug pricing trastuzumab is not considered cost-effective in several Latin American countries. 53 However, introduction of a lower-cost biosimilar to this region could make trastuzumab cost-effective and support decisions for drug funding and reimbursement, thereby improving patient access to HER2 therapy for treatment of HER2 þ breast cancer. Finally, many low-income countries rely on the WHO Model List of Essential Medicines to select or prioritize drugs for national essential or reimbursable medicine lists. 115 The WHO has initiated a pilot program, inviting manufacturers to submit applications for prequalification of rituximab and trastuzumab biosimilars into their Essential Medicines List. 116 Accordingly, implementation of this program might improve patient access to HER2 therapy for treatment of HER2 þ breast cancer.
Conclusions
Trastuzumab is standard treatment for HER2 þ breast cancer, but access to this drug remains limited even in some developed countries. Biosimilars offer an approach to expand access to biologic therapies by placing additional highly similar, high-quality products into clinical practice. In oncology practice, the first approved biosimilars (eg, epoetin and filgrastim) are used in supportive care, and have clinical effects that can be quickly and easily measured. Furthermore, extensive and required postapproval pharmacovigilance programs are in place to monitor for additional safety signals. This has provided clinicians with assurance about the safety and efficacy of these biosimilars. Monoclonal antibodies such as trastuzumab as anticancer drugs have effects on patient outcomes that are not as easily assessed. Understanding the scientific and regulatory aspects of biosimilar development will help clinicians be comfortable using a trastuzumab biosimilar across all clinical settings. Trastuzumab biosimilars are in development and might soon become available. The availability of safe and effective trastuzumab biosimilars might help address the need for increased trastuzumab access for patients with HER2
þ breast cancer worldwide. It is likely that trastuzumab biosimilars will be used in all indications for which the originator is approved; therefore, in addition to patients treated for breast cancer, patients with HER2 þ metastatic gastric or gastroesophageal junction adenocarcinoma might also benefit from the availability of trastuzumab biosimilars.
The introduction of trastuzumab biosimilars will be accompanied by the expectation of cost savings, although, with a projected discount of approximately 20% to 30%, 101 the cost savings are anticipated to be lower than with generic drugs. Nevertheless, trastuzumab biosimilars might expand use of HER2-targeted and other new therapies by generating savings for health care systems. Furthermore, biosimilars might provide greater economic benefits in emerging markets, 53 and other countries where cancer drugs are less affordable.
